These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26175846)

  • 1. Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol(®)-resistant ovarian cancer.
    Shen YA; Li WH; Chen PH; He CL; Chang YH; Chuang CM
    Am J Transl Res; 2015; 7(5):841-55. PubMed ID: 26175846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal (188)Re-Liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice.
    Shen YA; Lan KL; Chang CH; Lin LT; He CL; Chen PH; Lee TW; Lee YJ; Chuang CM
    Radiother Oncol; 2016 May; 119(2):282-90. PubMed ID: 26915312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer.
    Yuan H; Guo H; Luan X; He M; Li F; Burnett J; Truchan N; Sun D
    Mol Pharm; 2020 Jul; 17(7):2275-2286. PubMed ID: 32485107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis.
    Hribaschek A; Meyer F; Schneider-Stock R; Pross M; Ridwelski K; Lippert H
    Chemotherapy; 2007; 53(6):410-7. PubMed ID: 17952000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control.
    Shen YA; Shyu IL; Lu M; He CL; Hsu YM; Liang HF; Liu CP; Liu RS; Shen BJ; Wei YH; Chuang CM
    Int J Nanomedicine; 2015; 10():2485-502. PubMed ID: 25848266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
    Huang GS; Brouwer-Visser J; Ramirez MJ; Kim CH; Hebert TM; Lin J; Arias-Pulido H; Qualls CR; Prossnitz ER; Goldberg GL; Smith HO; Horwitz SB
    Clin Cancer Res; 2010 Jun; 16(11):2999-3010. PubMed ID: 20404007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 10. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
    Lee C
    Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicine-nanoemulsion formulation improves safety and efficacy of the anti-cancer drug paclitaxel according to preclinical assessment.
    Lee KC; Maturo C; Rodriguez R; Nguyen HL; Shorr R
    J Nanosci Nanotechnol; 2011 Aug; 11(8):6642-56. PubMed ID: 22103064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal administration of Taxol in the management of ovarian cancer.
    Markman M; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis JL; Rubin S; Curtin J; Barakat R; Almadrones L
    J Natl Cancer Inst Monogr; 1993; (15):103-6. PubMed ID: 7912515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
    [No Abstract]   [Full Text] [Related]  

  • 14. Reprogramming Cancer Stem-like Cells with Nanoforskolin Enhances the Efficacy of Paclitaxel in Targeting Breast Cancer.
    Singh D; Singh P; Pradhan A; Srivastava R; Sahoo SK
    ACS Appl Bio Mater; 2021 Apr; 4(4):3670-3685. PubMed ID: 35014452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Tong L; Chen W; Wu J; Li H
    Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes derived from Taxol-resistant nasopharyngeal carcinoma (NPC) cells transferred DDX53 to NPC cells and promoted cancer resistance to Taxol.
    Yuan F; Zhou ZF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):127-138. PubMed ID: 33506900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model.
    Ajorlou E; Khosroushahi AY; Yeganeh H
    Pharm Res; 2016 Jun; 33(6):1426-39. PubMed ID: 26908046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
    Iizuka K; Jin C; Eshima K; Hong MH; Eshima K; Fukushima M
    Drug Des Devel Ther; 2018; 12():673-683. PubMed ID: 29636601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol Impedes the Stemness, Epithelial-Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation.
    Shen YA; Lin CH; Chi WH; Wang CY; Hsieh YT; Wei YH; Chen YJ
    Evid Based Complement Alternat Med; 2013; 2013():590393. PubMed ID: 23737838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.